The Latest Cardiac and Vascular News
HANGZHOU, China, Dec. 7, 2021 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral and tricuspid valve treatment company on December 7th, 2021. […]
Cardiovalve becomes first privately held company to receive FDA’s early feasibility study (EFS) approval for both tricuspid regurgitation (TR) and mitral regurgitation (MR) indications OR YEHUDA, Israel–(BUSINESS WIRE)–Cardiovalve announced today that it has received U.S. Food and Drug Administration (FDA) approval for […]
OR YEHUDA, Israel, Sept. 20, 2018 /PRNewswire/ — Cardiovalve announced today that it has commenced the AHEAD USmulticenter study (U.S. Early Feasibility Study of High Surgical Risk Patients with Severe Mitral Regurgitation Treated with the Cardiovalve Transfemoral Mitral Valve System). AHEAD US trial recruitment will […]
